Phase III trial of adjuvant immunotherapy with MOAb 17–1A following resection for stage II adenocarcinoma of the colon (CALGB 9581)
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3522-3522
10.1200/jco.2004.22.90140.3522